Amedeo Ferdinando Capetti

8PUBLICATIONS
15CO-AUTHORS
Respiratory diseasesImmunogenetics (incl. genetic immunology)Major global burdens of diseaseInnate immunityColloid and surface chemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 27, 2023
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients.

Massimiliano Fabbiani, Melissa Masini, Barbara Rossetti

|May 05, 2022
Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects.

Fabio Borgonovo, Carlo Alberto Stangalini, Carmine Tinelli

|Jan 22, 2022
Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort.

Arturo Ciccullo, Gianmaria Baldin, Vanni Borghi

|Mar 11, 2021
Impressive Boosting of Anti-S1/S2 Immunoglobulin G Production in Coronavirus Disease 2019 (COVID-19)-experienced Patients After the First Shot of the BNT162b2 Messenger RNA COVID-19 Vaccine.

Amedeo F Capetti, Carlo A Stangalini, Fabio Borgonovo

|Sep 04, 2020
Short-term inhibition of SARS-CoV-2 by hydrogen peroxide in persistent nasopharyngeal carriers.

Amedeo F Capetti, Fabio Borgonovo, Valentina Morena

|Mar 21, 2019
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.

Amedeo F Capetti, Giuseppe V De Socio, Maria V Cossu

Pageof 2

Frequent Collaborators

3 joint publications

Gianmaria Baldin

2 joint publications

Massimiliano Fabbiani

2 joint publications

Gaetana Sterrantino

2 joint publications

Giuseppe Vittorio De Socio